当前位置:首页 >财报库 > 报告详情

嘉德诺Cardinal Health(CAH) 2026财年第二季度财报(10-Q)「NYSE」(英文版)(60页).pdf

上传人: 1****1 编号:1180573 2026-04-03 60页 743.79KB

下载:

1、Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549Form 10-QQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended December 31,2025orTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHA

2、NGE ACT OF 1934For the transition period from.to.Commission File Number:1-11373Cardinal Health,Inc.(Exact name of registrant as specified in its charter)Ohio31-0958666(State or other jurisdiction ofincorporation or organization)(IRS EmployerIdentification No.)7000 Cardinal Place,Dublin,Ohio43017(Add

3、ress of principal executive offices)(Zip Code)(614)757-5000(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon shares(without par value)CAHNew York Stock Exchan

4、geIndicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of1934 during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject tosuch fili

5、ng requirements for the past 90 days.Yes No oIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T(232.405 of this chapter)during the preceding 12 months(or for such shorter period that th

6、e registrant was required tosubmit such files).Yes No oIndicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a non-accelerated filer,a smaller reportingcompany,or an emerging growth company.See the definitions of“large accelerated filer,”“accelerated filer,”

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **财务表现**:2025财年前两季度营收129.6亿美元(同比+21%),GAAP运营利润13.75亿美元(同比+23%),Non-GAAP运营利润17.34亿美元(同比+38%)。 2. **业务增长**:Pharma部门营收119.9亿美元(+19%),受品牌药及专科药销售推动;GMPD部门营收6.44亿美元(+3%),客户需求增长。 3. **重大收购**:11月以19亿美元现金收购泌尿科MSO平台Solaris Health,并发行5亿美元股权激励。 4. **风险提示**:GLP-1药物需求波动、关税成本上升及潜在价格管制政策可能影响盈利。 5. **资本配置**:回购7.58亿美元股票,支付2.51亿美元股息,资本支出2.39亿美元。
**营收增长动力?** **GLP-1药物影响?** **关税应对策略?**
客服
商务合作
小程序
服务号
折叠